Revolution Medicines saw the highest growth of 1.66% in patent filings in May and 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Revolution Medicines‘s patent filings and grants. Buy the databook here.
Revolution Medicines has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 25% filings and 50% grants. The United States(US), World Intellectual Property Organization(WIPO), Israel(IL), and Australia(AU) patent Office are among the top ten patent offices where Revolution Medicines is filings its patents. Among the top granted patent authorities, Revolution Medicines has 50% of its grants in United States(US) and 50% in Israel(IL).
Roche could be the strongest competitor for Revolution Medicines
Patents related to rare diseases lead Revolution Medicines's portfolio
Revolution Medicines has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Leukemia related patents lead Revolution Medicines portfolio followed by noonan syndrome, and neuroblastoma
Revolution Medicines has highest number of patents in leukemia followed by noonan syndrome, neuroblastoma, melanoma.
For comprehensive analysis of Revolution Medicines's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.